Login
$MANE
$128.05 +$0.00 (0.0%) After hours

Company Executives

Management Team

From the 10-K annual report
Officer Age In this role Source
Reid Waldman Also a director
Chief Executive Officer and Director
31 Not stated
Dominic Carrano
Chief Financial Officer
40 Since 2025
1 year
Tim Durso
Chief Technical Officer
36 Since 2026
this year
Mark Neumann
Chief Commercial and Strategy Officer
62 Since 2025
1 year
Michael V. Greco
General Counsel
55 Since 2025
1 year
David Hollander
Chief R&D Officer
Title from the Form 4 dated Sep 1, 2026
Not stated Not stated
Timothy August Durso
Chief Technical Officer
Title from the Form 4 dated Aug 17, 2026
Not stated Not stated

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the 10-K annual report

Directors
7
serving now
Independent
0 of 1
stated in the proxy; 6 not stated
Average tenure
3.7 years
from year joined
Director Age On board Independent Committees Other public boards Pay Source
Reid Waldman
31 2019
7 years
Not independent None stated None stated Paid as CEO
John W. Childs
84 2021
5 years
Not stated
Audit Committee
Biohaven Ltd. Not stated
Vlad Coric
55 2021
5 years
Not stated
Compensation Committee · Chair
Biohaven, Royalty Pharma plc Not stated
Patrick Enright
64 2024
2 years
Not stated
Audit Committee · Chair
BioAge Labs, Inc. Not stated
David Friedman
51 2025
1 year
Not stated
Nominating and Corporate Governance Committee
None stated Not stated
Jane Grant-Kels
76 2021
5 years
Not stated
Nominating and Corporate Governance Committee · Chair
None stated Not stated
Katarina Pance
29 2025
1 year
Not stated
Audit Committee
None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No proxy statement on record

Related-party transactions come from the company’s proxy statement. Veradermics, Inc has not filed one with the SEC.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support